Valeant Pharmaceuticals Intl’s (VRX) Sector Perform Rating Reaffirmed at Royal Bank Of Canada
Royal Bank Of Canada reissued their sector perform rating on shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) in a research report released on Monday, StockTargetPrices.com reports. Royal Bank Of Canada currently has a C$39.00 price target on the specialty pharmaceutical company’s stock.
Other research analysts have also recently issued research reports about the stock. TD Securities reaffirmed a buy rating and issued a C$38.00 price target on shares of Valeant Pharmaceuticals Intl in a report on Wednesday, August 10th. Scotiabank decreased their price target on shares of Valeant Pharmaceuticals Intl from C$32.00 to C$17.00 and set a sector perform rating on the stock in a report on Wednesday, November 9th.
Shares of Valeant Pharmaceuticals Intl (TSE:VRX) opened at 23.47 on Monday. The firm’s market cap is $8.16 billion. Valeant Pharmaceuticals Intl has a 12-month low of $18.41 and a 12-month high of $165.77. The company’s 50 day moving average price is $26.29 and its 200 day moving average price is $31.45.
TRADEMARK VIOLATION WARNING: “Valeant Pharmaceuticals Intl’s (VRX) Sector Perform Rating Reaffirmed at Royal Bank Of Canada” was published by Financial Market News and is the sole property of of Financial Market News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of US & international copyright laws. The legal version of this news story can be viewed at http://www.financial-market-news.com/valeant-pharmaceuticals-intls-vrx-sector-perform-rating-reaffirmed-at-royal-bank-of-canada/1208082/.
Valeant Pharmaceuticals Intl Company Profile
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.